Maria Victoria M.
- Country
- Spain
- Department
- Hematology
Research Overview
- Evaluation of Humanized CAR T-Cell Therapy ARI0002h Targeting BCMA in Patients with Relapsed/Refractory Multiple Myeloma Resistant to Proteasome Inhibitors, Immunomodulators, and Anti-CD38 Antibody
- Evaluation of Safety and Pharmacokinetics of Forimtamig in Patients With Relapsed or Refractory Multiple Myeloma
- Phase 1 Dose-Escalation Study of CC-92328 in Patients with Relapsed/Refractory Multiple Myeloma
Data & Insights
Has run more than one trial at 57 of 109 partner sites.
Specializations
Multiple Myeloma Treatment
This investigator specializes in developing innovative therapies for multiple myeloma, with particular emphasis on treating relapsed and refractory cases. Their research encompasses both newly diagnosed patients and those who have undergone previous treatments.
- CAR T-cell therapies
- Bispecific antibodies
- Combination therapeutic approaches
Advanced Blood Cancers
The investigator focuses on treating complex blood disorders, including plasma cell leukemia and high-risk smoldering multiple myeloma. Their work involves evaluating novel therapeutic strategies for these challenging conditions.
- Immunotherapy approaches
- Target-specific treatments
- Early intervention strategies
Treatment Optimization
Research efforts concentrate on optimizing treatment protocols through combination therapies and maintenance strategies. The investigator evaluates various drug administration methods to enhance therapeutic outcomes.
- Drug sequencing studies
- Novel drug combinations
- Long-term treatment strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.